Trastuzumab deruxtecan
Trastuzumab deruxtecan, sold under the brand name Enhertu, is a monoclonal antibody medication used for the treatment of breast cancer or for the treatment of gastric or gastroesophageal adenocarcinoma. It was approved for medical use in the United States in December 2019, in Japan in March 2020, and in the European Union in January 2021.
primaryTopic
Trastuzumab deruxtecan
Trastuzumab deruxtecan, sold under the brand name Enhertu, is a monoclonal antibody medication used for the treatment of breast cancer or for the treatment of gastric or gastroesophageal adenocarcinoma. It was approved for medical use in the United States in December 2019, in Japan in March 2020, and in the European Union in January 2021.
has abstract
Trastuzumab deruxtecan, sold u ...... uropean Union in January 2021.
@en
alternative name
Enhertu
@en
CAS number
1826843-81-5
ChEMBL
chemical formula
C6460H9972N1724O2014S44.(C52H57F1N9O13)8
DrugBank
FDA UNII code
5384HK7574
KEGG
Link from a Wikipage to an external page
Wikipage page ID
62,630,349
page length (characters) of wiki page
Wikipage revision ID
1,017,459,266
Link from a Wikipage to another Wikipage
ATC prefix
L01
@en
ATC suffix
XC41
@en
CAS number
ChEMBL
chemical formula
C6460H9972N1724O2014S44.8
@en
DailyMedID
Trastuzumab_deruxtecan
@en
DrugBank
DB14962
@en
KEGG
D11529
@en
legal EU
Rx-only
@en
legal status
Rx-only
@en
legal US
Rx-only
@en
licence US
Enhertu
@en
mab type
mab
@en
PubChemSubstance
384,585,505
routes of administration
source
zu
@en
synonyms
DS-8201a, fam-trastuzumab deruxtecan-nxki
@en
target
tradename
Enhertu
@en
type
mab
@en
wikiPageUsesTemplate
subject
comment
Trastuzumab deruxtecan, sold u ...... uropean Union in January 2021.
@en
label
Trastuzumab deruxtecan
@en